𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK

✍ Scribed by Mike Aristides; Michael Lees; Nick Botwood; Jan McKendrick; DeborahA Stephenson; Nikos Maniadakis


Book ID
106294777
Publisher
Springer
Year
2003
Tongue
French
Weight
219 KB
Volume
4
Category
Article
ISSN
1618-7598

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


The pemetrexed/gemcitabine combination i
✍ Hedy Lee Kindler πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 89 KB

Gemcitabine has modest antitumor activity in advanced pancreatic cancer. New agents are clearly needed. Pemetrexed (ALIMTA) is a novel antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has shown in vitro activity agai

Combined gemcitabine and radioimmunother
✍ Thomas M. Cardillo; Rosalyn Blumenthal; Zhiliang Ying; David V. Gold πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 116 KB πŸ‘ 1 views

## Abstract MAb‐PAM4 is an anti‐MUC1 antibody that has been shown to be reactive with 85% of pancreatic adenocarcinomas with no reactivity with normal pancreas or other tissues. Initial clinical studies have shown excellent targeting with high tumor/nontumor ratios. Gemcitabine, an analog of deoxyc

On the development of gemcitabine-based
✍ Cornelius J. McGinn; Theodore S. Lawrence; Mark M. Zalupski πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 107 KB

The use of chemotherapy with concurrent radiation therapy remains a standard treatment option for patients with unresectable or resected adenocarcinoma of the pancreas. This treatment strategy is based in large part on data from serial Gastrointestinal Tumor Study Group trials that have included 5-f